Portfolio

Focusing on the Future of
Precision Health

At MEC, we believe the technologies created in this decade will lead to a golden age in innovation within the life sciences space. MEC invests in company creation, seed, Series A, and Series B opportunities where technology and novel approaches are transformative for patient care and directly address large, unmet needs. Our areas of focus include, but are not limited to:

AI to Advance Drug Discovery

The use of algorithms and advanced digital processing to find new, more effective therapies and reduce the cost of developing drugs.

Cell and Gene Therapy

The therapeutic methodologies designed to replace, inactivate, or introduce a new gene to treat disease. The transplantation of human cells to replace diseased or missing cells.

Precision
Medicine

Predictive, data-driven diagnostics or treatments in which prevention and care strategies are highly customized according to an individual’s genes, lifestyle, and environment.

Regenerative Medicine

Scientific methods designed to repair, regrow, or replace damaged or diseased cells, tissues, or organs.

Synthetic
Biology

Redesigning or re-engineering and assembling new biological systems by combining non-living and live biomolecular components.

OUR PORTFOLIO

Immunitas Therapeutics
Active
NAME: Immunitas Therapeutics
Founded: 2019
Location: Boston, MA
MEC Theme: AI/ML for drug discovery and development
Immunitas Therapeutics

Immunitas is a single cell genomics-based therapeutics company focused on immunology that is advancing multiple programs to the clinic. The company was founded by Longwood Fund with leading scientists from Dana-Farber Cancer Institute, Massachusetts General Hospital, the Broad Institute at Harvard, and MIT (Massachusetts Institute of Technology). Immunitas’ programs are derived from their platform, a cross-functional, highly integrated, single-cell genomics approach that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class NK (Natural Killer) and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. Immunitas is also advancing IMT-073, a dual-target NK and T cell modulator. Since being founded in 2019, Immunitas has raised a total of $97 million in venture funding from a strong syndicate of investors including Longwood Fund, Alexandria Ventures, Evotec, Leaps by Bayer, M Ventures, and Novartis Venture Fund (NVF).

Website: www.immunitastx.com

Nobias Therapeutics
Active
Name: Nobias Therapeutics
Founded: 2020
Location: Philadelphia, PA
Stage: Series A
MEC Theme: AI/ML for drug discovery and development
Nobias Therapeutics

Nobias Therapeutics is a spinout from the Children’s Hospital of Philadelphia (CHOP) focused on artificial intelligence and machine learning-aided analysis of genotypes and clinical records to develop new therapies designed to cure illnesses in children. The company was founded in 2020 by MEC Managing Partner, Brian Halak and Dr. Hakon Hakonarson. Dr. Hakonarson is the Founding Director of the Center for Applied Genomics and Endowed Chair in Genomics Research at CHOP and Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Nobias has two programs entering clinical trials that address the genetic basis of two different rare diseases in children and has discovery programs in a variety of rare and common diseases.

Website: Coming Soon

ProJenX
Active
Name: ProJenX
Founded: 2021
Location: New York City, NY
Stage: Company Creation/Seed
MEC Theme: Regenerative Medicine
ProJenX

ProJenX is a MEC company creation effort focused on the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases.

Website: Coming Soon

Rejuvitas
Active
Name: Rejuvitas
Founded: 2021
Location: New York City, NY
Stage: Company Creation/Seed
MEC Theme: Gene Therapy
Rejuvitas

Rejuvitas is a MEC company creation effort committed to developing gene therapies focused on metabolic dysregulation that addresses the underlying common cause of neurodegeneration.

Website: Coming Soon